Abstract

GENOMICS,GENETICSANDEPIGENETICSRESEARCHPROGRAM PROGRAMCODE:GGE PROJECTSUMMARY/ABSTRACT TheGenomics,GeneticsandEpigenetics(GGE)program(formerlytheCancerGeneticsandGenomics Program)consistsof48memberswhobelongto15differentacademicdepartmentsandareboundtogether bysharedinterestinstudyingthecancergenomeandepigenomeandtranslatingthisknowledgeintonew drugs,noveltherapeuticstrategies,andnoveldiagnostictests.Theprogramadoptedanewnamein2015by including?epigenetics?intheprogramtitletoreflectincreasinginterestbyitsmembersinepigeneticresearch. Theprogramhasthreemajorresearchthemes:1)identifyandcharacterizegeneticandepigeneticchanges thatdrivecancerformationandprogression;?2)developnewanalyticaltools,dataresources,andnovel laboratorymodelsthatenablegeneticallydriventherapeuticapproachesanddiagnostictests;?and3)translate thegenomicandgenetic/epigeneticdiscoveriesintonoveldrugsandnewdiagnostictests.Thesegoalsare accomplishedthroughprogrammaticinteractionbetweenlaboratoryscientists,clinicians/clinicaltrialists,and computationalbiologists.ThemostimportantfunctionoftheGGEprogramistofostercollaborations,guide recruitment,andprovidetechnologytoaccomplishthesegoals.Weorganizemonthlyresearchseminarsin whichmemberspresenttheirresearchprojectstodisseminateinformationacrosstheprogram.Wehold retreats/symposiaonrelevantcancergeneticstopicsandprogramleadersactivelyworkoncollaborative ?matchmaking?tobringtogethernewresearchteams,includingbasicandclinicalresearchers,toadvance cancerresearch.Throughthesemechanisms,sinceourlastrenewal,wehaverecruited19newmembersand increasedourtotalmembershipfrom44in2012to48in2017.Wealsocreatedseveralnewmultidisciplinary researchteams,establishedseveralnewinvestigator-initiatedclinicaltrialsledbyGGEmembers,and increasedcollaborationbothwithintheprogramandbetweenYCCprograms.Wealsoincreasedourtotal fundingbase.InJune2017,thetotalresearchfundingoftheprogramwas$11.5M,whichisa40% increasecomparedto$8.2M(alldirectcosts)atthetimeofthelastCCSGrenewalin2012.Totalpeer- reviewedfundingis$8.6M,ofwhich$1.9M(directcosts)comefromNCI.GGEmemberspublished718 cancer-relatedpapersbetweenJuly2012andJune2017,ofwhich17%wereintra-programmatic,30%inter- programmaticand66%collaborativepublicationswithinvestigatorsfromotherinstitutions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016359-39S4
Application #
9772330
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code

  Publications

Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications